Optimizing Outcomes in Gastrointestinal Stromal Tumors: A Surgeon’s Perspective

Gastrointestinal stromal tumors (GISTs) typically originate in the stomach (60%-70%), followed by the small intestine (20%-30%), with less frequent occurrences in the colon, rectum, and esophagus. The location of the tumor significantly affects both its clinical presentation and treatment approach. Gastric GISTs generally have a better prognosis, while tumors in the small intestine or rectum are associated with a higher likelihood of aggressive growth and recurrence. Surgical resection is the cornerstone of treatment for localized GISTs, with the aim of achieving a complete (R0) resection with negative margins. Preserving tumor integrity during surgery is critical, as rupture could lead to peritoneal spread and worsen outcomes. Minimally invasive surgery may be an option for smaller tumors in favorable locations, while larger or more complex cases may require open surgery. In addition to surgery, tyrosine kinase inhibitors are integral to the treatment of GISTs, especially in cases where the tumor is unresectable, metastatic, or at a high risk of recurrence. Agents such as imatinib have revolutionized GIST treatment, offering neoadjuvant therapy to shrink tumors prior to surgery and adjuvant therapy to reduce recurrence risk after surgery. Long-term monitoring with regular imaging is essential, particularly in high-risk patients, due to the potential for late recurrences. Familiarity with these management strategies is vital for optimizing patient outcomes in GIST care.